MedTrace Logo

Circulating Tumor DNA Guided Adjuvant Chemotherapy for Biliary Tract Carcinoma

NCT06171321 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2023-12-14

No results posted yet for this study

Summary

In recent years, circulating tumor DNA (ctDNA)had achieved encouraging results in monitoring recurrence and metastasis after surgery, and has potential clinical application value. The presence of ctDNA after surgery predicts very poor recurrence-free survival, whereas its absence predicts a low risk of recurrence. The benefit of adjuvant chemotherapy for ctDNA-positive patients is not well understood.

Conditions

  • Biliary Tract Cancer

Interventions

DRUG

S-1(Intravenous combined with oral)

Oral combined with intravenous S-1 for ctDNA-positive patients (escalating treatment strategy)

Sponsors & Collaborators

  • Shanghai East Hospital

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-31
Primary Completion
2025-11-15
Completion
2026-04-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06171321 on ClinicalTrials.gov